SUBSCRIBE: Print / Digital / eNewsletter
At AMCP 2019, Cate Lockhart, MS, PharmD, PhD, executive director at Biologics and Biosimilars Collective Intelligence Consortium, discusses accelerating the uptake of biosimilars in the U.S. market.
At AMCP 2019, C.E. (Gene) Reeder, RPh, PhD, director of outcomes research at the University of South Carolina, sheds light on the specialty drug category and the state of pharma rebate contracting.
At AMCP 2019, Kenneth Schaecher, MD, associate chief medical officer, University of Utah Health Plans, Salt Lake City, addresses the challenges of value-based outcomes measurement.
At AMCP 2019, Kristin D. Brown-Gentry, MS, senior health outcomes scientist, Magellan Rx Management, talks about using predictive analytics to optimize pharmaceutical outcomes.
At AMCP 2019, Jann R. Rigell, RPh, MBA, principal, Enterprise Specialty Programs, MedImpact Direct, shares strategies to rein in specialty drugs costs.
At AMCP NEXUS 2019, Susan Trieu, PharmD, director of Enterprise Specialty Clinical Solutions for MedImpact Healthcare Systems, Inc, predicts the top specialty drug categories that will be driving spend in 2020.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
